Skip to main content

Long-Time Board Member Frances P. Philip Announces She Will Not Be Standing for Re-Election at 2025 Shareholder Meeting

FORT WAYNE, Ind., April 18, 2025 (GLOBE NEWSWIRE) — Vera Bradley (NASDAQ: VRA) (the “Company”) today announced that long-time board member Frances P. Philip will not stand for re-election at the upcoming 2025 Shareholder Meeting. Ms. Philip joined the Company’s Board in 2011 and has served as a member on both the Talent and Compensation Committee, as well as the Nominating, Governance and Sustainability Committee during her tenure. Ms. Philip has served as the Lead Independent Director since 2022, overseeing the Company’s business with insights stemming from the extensive product development, branding, marketing, and retail experience she possesses. Robert Hall, Chairman of the Vera Bradley board of Directors, commented, “Frances has been a highly respected and influential member of the Company’s Board of Directors over the past...

Continue reading

Verizon to report earnings April 22, 2025

NEW YORK, April 18, 2025 (GLOBE NEWSWIRE) — Verizon Communications Inc. (NYSE, Nasdaq: VZ) will report first-quarter 2025 earnings on Tuesday, April 22. The company will present results on a webcast beginning at 8:30 a.m. Eastern Time. First-quarter 2025 materials will be available at 7:00 a.m. ET on Verizon’s Investor Relations website, https://www.verizon.com/about/investors. These materials will include:Detailed information on Verizon’s first quarter results, including a recording and transcript of management’s commentary; Verizon’s earnings news release; and Financial tables.Verizon Communications Inc. (NYSE, Nasdaq: VZ) powers and empowers how its millions of customers live, work and play, delivering on their demand for mobility, reliable network connectivity and security. Headquartered in New York City, serving...

Continue reading

Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approved TARRYTOWN, N.Y. and PARIS, April 18, 2025 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment. “People with chronic spontaneous urticaria experience sudden, unpredictable...

Continue reading

Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatment CSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment. Kenneth MendezPresident and Chief Executive Officer at the Asthma and...

Continue reading

Christian Dior: 2024 Dividend

Paris, April 18th, 2025 2024 DIVIDEND At the Annual Shareholders’ Meeting of Christian Dior held on Thursday, April 17th, 2025, approval was given for the payment of a dividend for financial year 2024 of 13 Euros per share. Taking into account the 5.50 Euros paid on Wednesday, December 4th, 2024, the balance amounts to 7.50 Euros; it will be paid on Monday, April 28th, 2025. The last trading day with dividend rights is Wednesday, April 23rd, 2025. This financial release is available on our website www.dior-finance.com.AttachmentChristian-Dior-Dividend-2024 EN

Continue reading

LVMH: 2024 Dividend

Paris, Friday, April 18th, 2025 At the Annual Shareholders’ Meeting of LVMH Moët Hennessy Louis Vuitton held on Thursday, April 17th, 2025, approval was given for the payment of a dividend for financial year 2024 of 13.00 Euros per share.Taking into account the 5.50 Euros paid on Wednesday, December 4th, 2024, the balance of 7.50 Euros will be paid on Monday, April 28th, 2025. The last trading day with dividend rights is Wednesday, April 23rd, 2025. LVMHLVMH Moët Hennessy Louis Vuitton is represented in Wines and Spirits by a portfolio of brands that includes Moët & Chandon, Dom Pérignon, Veuve Clicquot, Krug, Ruinart, Mercier, Château d’Yquem, Domaine du Clos des Lambrays, Château Cheval Blanc, Colgin Cellars, Hennessy, Glenmorangie, Ardbeg, Belvedere, Woodinville, Volcán de mi Tierra, Chandon, Cloudy Bay, Terrazas de los Andes,...

Continue reading

DISCLOSURE OF SHARE CAPITAL AND VOTING RIGHTS

Boulogne-Billancourt, April 18, 2025 Disclosure of Share Capital and Voting Rights(Pursuant to Article L.233-8 II of the French Commercial Code and Article 223-16 of the general Regulations of the Autorités des Marchés Financiers) Registered name of the issuer: CEGEDIM SADate Shares outstanding Total potential voting rights Exercisable voting rights*March 31, 2025 14,097,155 22,031,685 21,700,558* excluding rights attached to share held in treasuryAttachmentDisclosure-share-VR-31march2025

Continue reading

Healthcare Integrated Technologies Inc. Appoints Theo Davies as Chief Revenue Officer

Mr. Davies was Previously the Company’s Chief Commercial Officer Knoxville, TN, April 18, 2025 (GLOBE NEWSWIRE) — Healthcare Integrated Technologies Inc. (OTC PINK: HITC), a global leader in AI-driven safety and monitoring solutions, proudly announces the appointment of Theo Davies from Chief Commercial Officer to Chief Revenue Officer (“CRO”), effective immediately. Prior to Mr. Davies being the Company’s Chief Commercial Officer, Mr. Davies was a former Google executive, who was the Head of Sales Enablement for Asia-Pacific. Mr. Davies continues to bring a wealth of global expertise and leadership to HITC. His exceptional background, including a master’s in mathematics, from the University of Edinburgh and an MBA from India’s top business school, SP Jain, Mr. Davies has consistently demonstrated his ability to develop world-class...

Continue reading

ASUS Introduces Upgraded TUF Gaming A14 for Ultimate Performance

The new A14 combines an ultraportable design with outstanding AI-enhanced performanceTORONTO, April 18, 2025 (GLOBE NEWSWIRE) — ASUS today announced an all-new ASUS TUF Gaming A14 equipped with an AMD Ryzen™ AI 7 350 CPU and an NVIDIA® GeForce RTX™ 5060 Laptop GPU. Housed in an incredibly portable and lightweight 14-inch form factor chassis, the TUF Gaming A14 is the perfect companion for any gamer on the go. Next-gen RTX™ 50 Series graphics Backed by the incredible performance of the new NVIDIA® GeForce RTX™ 5060 Laptop GPU, the TUF Gaming A14 is truly primed and ready for the latest AAA and esports games. This card features the latest DLSS suite of technologies, which uses AI and neural rendering to boost FPS, reduce latency, and improve image quality. The latest breakthrough, DLSS 4, brings new...

Continue reading

ES Bancshares, Inc. Announces First Quarter 2025 Results; Continues Positive Trend of Net Income and Net Interest Margin Expansion

STATEN ISLAND, N.Y., April 18, 2025 (GLOBE NEWSWIRE) — ES Bancshares, Inc. (OTCQX: ESBS) (the “Company”) the holding company for Empire State Bank, (the “Bank”) today reported net income of $546 thousand, or $0.08 per diluted common share, for the quarter ended March 31, 2025, compared to a net income of $466 thousand, or $0.07 per diluted common share for the quarter ended December 31, 2024.Key Quarterly Financial Data 2025 Highlights    Performance Metrics 1Q25 4Q24   1Q24   • The Cost of Funds for the three months ended March 31, 2025, improved to 2.69% from 2.87% in the prior linked quarter. • For 3 months ended March 31, 2025, the Company’s net interest margin increased to 2.68% compared to 2.50% for the 3 months ended December 31, 2024. • The Company sold $3 million in SBA 7a loan during the quarter, resulting in...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.